Last reviewed · How we verify
sodium valproate with Clozapine
This combination pairs sodium valproate (a histone deacetylase inhibitor and GABA enhancer) with clozapine (an atypical antipsychotic) to provide synergistic effects on mood stabilization and antipsychotic activity.
This combination pairs sodium valproate (a histone deacetylase inhibitor and GABA enhancer) with clozapine (an atypical antipsychotic) to provide synergistic effects on mood stabilization and antipsychotic activity. Used for Schizophrenia (treatment-resistant or acute exacerbation), Bipolar disorder with psychotic features.
At a glance
| Generic name | sodium valproate with Clozapine |
|---|---|
| Also known as | Valproate |
| Sponsor | Shanghai Mental Health Center |
| Drug class | Antipsychotic + mood stabilizer combination |
| Target | Dopamine D2 receptor, serotonin 5-HT2A receptor, GABA pathways, histone deacetylase |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | FDA-approved |
Mechanism of action
Sodium valproate enhances GABAergic neurotransmission and inhibits histone deacetylases, providing mood-stabilizing and neuroprotective effects. Clozapine is a second-generation antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors. Together, they target multiple neurotransmitter systems implicated in psychotic and mood disorders, potentially improving efficacy in treatment-resistant conditions.
Approved indications
- Schizophrenia (treatment-resistant or acute exacerbation)
- Bipolar disorder with psychotic features
Common side effects
- Sedation
- Weight gain
- Metabolic syndrome
- Tremor
- Agranulocytosis (clozapine-related)
- Orthostatic hypotension
- Anticholinergic effects
Key clinical trials
- Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure (PHASE3)
- Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy (PHASE4)
- The Optimal Treatment for Treatment-resistant Schizophrenia (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- sodium valproate with Clozapine CI brief — competitive landscape report
- sodium valproate with Clozapine updates RSS · CI watch RSS
- Shanghai Mental Health Center portfolio CI